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INTRODUCTION
Exercise limitation is a common complain of patients 
with chronic obstructive pulmonary disease (COPD) 
and deteriorates their quality of life1,2,3. Exercise limi-
tation has traditionally been attributed to the increased 
work of breathing and the dynamic hyperinflation that 
result from airflow limitation4. Resent studies have 
provided evidence that COPD is a systematic disease 
that is associated with extrapulmonary abnormalities, 
such weight loss, skeletal muscle dysfunction and 
signs of systemic inflammation5. The systemic effects 
of COPD are important clinical features and contrib-
ute significantly to the aggravation of exercise capac-
ity and health status5,6.
Leptin, a protein mainly secreted by adipocytes, 
plays an important role in body weight regulation. In-
creased levels of circulating leptin may contribute to 
anorexia and weight loss in many pathologic condi-
tions including COPD7. Recent studies have provided 
evidence for a link between leptin and proinflamma-
tory cytokines, as TNF-a. In animals, the administra-
tion of TNF-a or interleukin 1 (IL-1) - inflammatory 
cytokines with anorectic effects- resulted in a dose 
dependent upregulation of leptin mRNA in fat cells 
and an increase in circulating leptin concentrations8. 
In stable patients with emphysema leptin was found to 
be positively related to plasma TNF-a receptor 559.
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Circulating leptin and TNF-a levels correlated 
with BMI and % fat in COPD patients10. In malnour-
ished COPD patients, there was an inverse relation-
ship between changes in body weight after 8 weeks of 
nutritional therapy and leptin plasma concentrations9. 
The nutritional parameters that express muscle mass, 
as FFM, were reported to be associated with exercise 
performance in COPD patients11,12.
Extrapulmonary abnormalities, like systemic in-
flammation, weight loss and muscle dysfunction, de-
termined the exercise capacity of COPD patients and 
were related with leptin and TNF-a levels. The aim 
of the present study is to examine whether the limita-
tion of the exercise capacity of these patients can be 
related to the circulating serum leptin and TNF-alpha 
levels. 
MATeRiAl And MeThodS
Thirty male patients with moderate to severe COPD, 
defined by a FEV1/FVC of less than 0.50, were evalu-
ated. Patients with other potential causes of weight loss 
such as diabetes, thyroid dysfunction, malabsorption 
syndromes, alcoholism and neoplastic diseases were 
excluded. Patients with edema forming states, i.e. re-
nal, liver or cardiac diseases, were also excluded in 
order to eliminate the effect of edema in the interpre-
tation of body weight. At the time of the study, all the 
patients were stable and all received optimal medical 
therapy including a low dose of methylprednisolone 
(4-8 mg every other day) for 1-2 months (mean dura-
tion 37± 12 days). Corticosteroid treatment was in-
stalled in our COPD patients during last exacerbation 
and tapered in small doses. None of our subjects were 
in long term high doses oral corticosteroid treatment. 
The study was approved by the Ethics Committee of 
the G Papanikolaou Hospital (University Hospital) of 
Thessaloniki. All patients gave written informed con-
sent before inclusion.
Spirometry was performed with a computerized 
spirometer (Jaeger) and Forced Expiratory Volume in 
one second (FEV1), Forced Vital Capacity (FVC) and 
the ratio FEV1/FVC (FEV1%) were calculated accord-
ing to the ATS recommendations13. The results were 
expressed as absolute values and as percent of the pre-
dicted values.
Body height (h) was determined to the nearest 0.5 
cm (Lameris WM 715, Breukelen) with the patients 
standing barefoot. Body weight (Bw) was measured 
with a beam scale to the nearest 0.1 kg (SELA, FR-G) 
with subjects barefoot and with only underwear cloth-
ing. Body Mass Index (BMI) was calculated from 
body weight and height (BMI = Bw/h2, kg/m2).
The measurement of skinfold thickness at four 
sites (triceps, biceps, subcapular, suprailiac) was used 
to assess fat mass. Total fat mass (FM) was estimated 
using tables and free fat mass (FFM) was obtained by 
the subtraction of FM from Bw14. Forceps skinfold 
thickness (FST) and mid-thigh circumference (MTC) 
were used to calculate the mid-thigh muscle circum-
ference (MTMC). Finally, thigh muscle area (TMA) 
was calculated (TMA = MTMC2/4π)15.
Exercise testing was done on a cycle ergometer 
(cardiopulmonary Diagnostic System Med Graph-
ics), using the standard 1-min incremental cycle ex-
ercise protocol. Patients began with a 2-min period of 
unloaded pedaling at 60 cycles/min, followed by 10 
Watt increments per minute. The patients were strong-
ly encouraged to cycle to the point of discomfort or 
exhaustion or until an abnormal electrocardiogram 
(ECG) was noted (symptom-limited exercise tests). 
Heart Rate (HR) and cardiac rhythm were monitored 
with a three-lead ECG and blood pressure was mea-
sured with auscultation.
Minute ventilation and its components were mea-
sured with a pneumotachograph. The concentrations 
of expired O2 and CO2 were analyzed breath by breath 
with a zirconium dioxide-cell O2 analyzer and an in-
frared CO
2 
analyzer respectively. These measurements 
and the pneumonotachograph flow signals were in-
tegrated electronically by a computerized system to 
yield 10-s averages of minute ventilation (VE), tidal 
volume (V
T
), respiratory rate (RR), oxygen uptake 
(V
O2
), carbon dioxide output (V
CO2
) and gas exchange 
ratio (R). HR was also measured and was used to 
obtain the HR reserve (HRmax/predHRmax %) and 
O2 pulse (VO2/HR). Maximal O2 pulse (O2Pmax) was 
measured at the point at which O2 pulse reached a 
plateau or patients were exhausted. Predicted Maxi-
mal Voluntary Ventilation (MVV) was expressed as 
MVV= FEV1 x 35, in units of L/min, and predicted 
maximal HR (HRmax) was calculated as 210- (age x 
0.65)15. Arterial hemoglobin oxygen saturation (Sa
O2
) 
was monitored non invasively with a pulse oximeter. 
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For leptin levels determination blood samples 
were drawn between 8-9 a.m. after fasting the pre-
vious night. The samples were stored at -70oC until 
analysis. Serum leptin levels were determined using a 
competitive enzyme immunoassay (Accucyte, Mery-
land USA). TNF-a levels were determined in serum 
using Pelikine Compact human TNF-a ELISA kits 
(CLB, Amsterdam). The specificity of the ELISA kit 
is 0-1000 pg/mL for TNF-a. In 10 normal subjects 
(age 63+5y) the serum leptin levels were 3.67 +0.7 
ng/mL and TNF-a levels were 3.11+ 0.45 pg/mL.
STATiSTiCAl AnAlySiS
Values obtained were expressed as mean + SD. Pear-
son’s correlation coefficients were calculated among 
V
O2max
 or maximal exercise capacity (in watts) and 
different metabolic and exercise parameters. Stepwise 
multiple regression analysis was performed to deter-
mine the best predictors of V
O2max
. 
ResUlTs
Anthropometric and lung function data of our 30 
COPD patients (mean age 68,7+1.06 years) presented 
in Table 1. TNF-a levels were 9.58+0.56 pg/mL (range 
5.65-16.7 pg/mL) and serum leptin concentration was 
9.37+1.7ng/mL (range 1.17-37.4 ng/mL), increased in 
relation to our normal values.
There was a significant correlation between se-
rum TNF-a and leptin levels (r = 0.521, p < 0.001). 
Also there were significant correlations between se-
rum leptin levels, BMI (r = 0.421, p < 0.02) and FM 
(r = 0.551, p < 0.01), but no correlations were found 
between serum leptin levels and other nutritional pa-
rameters such as FFM, MTMC or TMA. Also no cor-
relations were found between nutritional parameters 
like BMI, FM, FFM, MTMC, TMA and serum TNF-a 
levels.
The exercise capacity, the ventilatory and cir-
culatory parameters during maximal exercise of 
the COPD patients of the study are presented in ta-
ble 2. Patients with COPD achieved a work capac-
ity (Wmax) of 42.6+5.43 watts (30.2+3.43% of pre-
dicted normal values). V
Emax
 was 31.3+2.05 L/min, 
MVV was 35.98+2.48 L/min and V
Emax
/MVV was 
95.8+3.87. V
O2
max was decreased (786+57mL/min). 
Maximal heart rate (HRmax) was 121.7+5 beats/min 
(85.7+2.3% of predicted). The oxygen pulse (V
O2max
/
HRmax) was decreased during maximal exercise 
(6.47+1.17 mL/beat).
The correlations between exercise capacity (Wmax 
or V
O2
max) and ventilatory, circulatory and nutritional 
parameters are presented in table 3. The exercise ca-
pacity correlated significantly with %FEV1 and oxy-
Table 1. Study population: anthropometric and spirometric data (mean + SE).
Age, years 68.7+1.06
Weight, kg 71.5+2.74
BMI, kg/m2 26.1+0.95
FM, kg 20.9+1.53
FFM, kg 50.8+1.60
MTMC, cm 44.4+1.97
TMA, cm2 121.7+8.39
FVC, L 2.18+0.10
FEV1, L/sec 1.02+0.05
% FEV1 43.1+1.84
TLC, %pred 92.1+3.96
BMI: body mass index, FM: fat mass, FFM: fat free mass, MTMC: mid-thigh muscle circumference, TMA: thigh muscle 
area, F�C: Forced �ital Capacity, FE�     
1
: Forced Expiratory �olume in one second, TLC: Total Lung Capacity.
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gen pulse (V
O2
/HR) but not with V
Emax
/MVV or HR-
max. The exercise capacity correlated significantly 
better with BMI and TMA than with FFM. We found 
no correlations between leptin and TNF-a serum lev-
els and exercise capacity of the COPD patients of the 
study.
Stepwise multiple regression analysis was per-
formed to determine the best predictors for V
O2
max. It 
demonstrated that % FEV1 and TMA were significant 
determinants of V
O2max
. In contrast serum leptin and 
TNF-a were not selected as significant predictors of 
V
O2max
. According to the above V
O2max
 was expressed 
as: 
V
O2max 
= 0.329 % FEV1 + 0.495 TMA + 211 
(R2 = 0.520) 
DIsCUssION
COPD patients stop exercise when either dyspnea or 
leg effort reach a severe intensity. Dyspnea-limited 
exercise is more frequent in patients with severe air-
flow limitation and V
O2max 
is a more objective index 
of work during maximal exercise than dyspnea or leg 
effort sensation. It is open to question whether maxi-
mal ventilatory and circulatory capacities are actually 
reached during exercise.
In the present study the work capacity was signifi-
cantly decreased in patients with severe airflow limi-
tation. In the COPD patients of the current study the 
work capacity (expressed as Wmax or V
O2max
) related 
to the flow limitation (%FEV1), but not to the dyspnoe-
ic index (V
Emax
/MVV) (table 3). Also the work capac-
Table 2. Exercise capacity, ventilatory and circulatory parameters (mean + SE).
Wmax, Watts 42.57+5.43
Wmax, %pred 30.20+3.43
V
O2
max, mL/min 786+57
VEmax, L/min 31.30+2.05
VEmax/MVV, % 95.80+3.87
HRmax , b/min 121.70+5.00
HRmax/ HRpred, % 85.7+2.30
V
O2
max/ HRmax, mL 6.47+1.17
MVV, L/min 35.98+2.48
Wmax: work capacity, �
O�
max: maximal oxygen uptake, �    
E
max: maximal ventilation, HRmax: maximal heart rate, �       
O�
max/ 
HRmax: maximal oxygen pulse, M��: Maximal �oluntary �entilation.       
Table 3. Correlation coefficients (r) between exercise capacity (Wmax, V
O2max
), ventilatory, circulatory, nutritional param-
eters, leptin and TNF-a levels. 
Work 
capacity
% FEV1 VEmax/MVV
(%)
HRmax/pred
(%)
V
O2
/HR
mL
BMI
Kg/m2
FFM
kg
TMA
cm2
Leptin
ng/mL
TNF-a
pg/mL
Wmax, 
watts
0.435
p<0.05
0.232
NS
0.093
NS
0.775
p<0.001
0.578
p<0.001
0.295
NS
0.623
p<0.001
-0.013
 NS
0.068
NS
V
O2max,
 ,
mL/min
0.563
p<0.01
0.245
NS
0.09
NS
0.917
p<0.001
0.636
p<0.001
0.415
p<0.02
0.651
p<0.001
0.208
NS
0.250
NS
Wmax: work capacity, M��: Maximal �oluntary �entilation, �   
O�
max: maximal oxygen uptake, �    
E
max: maximal ventilation,   
HRmax: maximal heart rate, �
O�
max/ HRmax: maximal oxygen pulse, BMI: body mass index, FFM: fat free mass, TMA:             
thigh muscle area.
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ity related with the oxygen pulse (V
O2
max/HRmax), 
but not with the maximal heart rate (HRmax/HRmax 
pred). 
The absence of statistically significant correlations 
between exercise capacity and ventilatory (V
Emax
/
MVV) or circulatory (HRmax/ HRmax pred) param-
eters in the present study suggested that most subjects 
stopped exercise at submaximal heart rate and venti-
lation. Possibly the symptoms rather than the physio-
logic factors limited the work capacity16. Hence it was 
reasonable to expect that the average patient would 
stop exercise when dyspnoea (mainly related to flow 
limitation) or the intensity of symptoms of leg effort 
were maximal.
Weight loss commonly occurs in patients with 
COPD and it is not only an epiphenomenon of the se-
verity of the disease but also an independent death risk 
factor. Weight loss and muscle wasting are factors ex-
erting several adverse effects on physical performance 
and respiratory muscle function, independently of the 
degree of airflow obstruction17-19. In this study patients 
with COPD and low BMI had diminished V
O2max 
dur-
ing exercise.
FFM that represents muscles mass is associat-
ed with respiratory muscles strength20 and exercise 
performance11. The patients of the study with the 
higher FFM had an increased V
O2max 
during exercise 
(r = 0.415, p < 0.02). Total FFM was a significant de-
terminant of V
O2max
 in patients with COPD21.
The distribution of muscle mass wasting is a fac-
tor that has to be elucidated, since muscle strength 
is closely related to muscle mass in patients with 
COPD21. FFM of legs is a significant predictor of 
maximal exercise performance in patients with mod-
erate airflow limitation22. TMA of the patients of this 
study reflected the muscle mass of the legs and cor-
related better with V
O2max
, compared with FFM.
Body composition analysis by dual energy X-ray 
absorptiometry in COPD patients with severe airflow 
limitation demonstrated disproportional leg muscle 
wasting21. The distribution of muscle wasting found in 
COPD patients was not related to the atrophy induced 
by malnutrition. In malnutrition the loss of upper-limb 
function was equal or greater than that of the lower 
limbs23. In contrast in patients with severe COPD a 
disproportional leg muscle wasting was found. The 
leg muscle wasting could be attributed to the limita-
tion of the daily activity of COPD patients and also to 
the limited respiratory reserve22,23.
Systemic inflammation plays an important role in 
skeletal muscles dysfunction in COPD patients. The 
systemic inflammation is a characteristic feature of 
COPD and is demonstrated by the increased numbers 
of neutrophils, macrophages and T-lymphocytes, as 
well as by the elevated concentrations of pro-inflam-
matory cytokines and by the oxidative stress. In clini-
cally stable patients, but especially during the exacer-
bations of the disease, increased levels of cytokines, 
such TNF-a and its receptors (TNFR-55, TNFR-75), 
interleukin -6 and -8 (IL-6, IL-8), as well as elevated 
levels of acute phase proteins, like C-reactive protein 
(CRP) and liposaccharide-binding protein (LBP) were 
found24,25. Submaximal exercise induced an abnormal 
increase in plasma TNF-a and IL-6 in patients with 
COPD [26]. Serum TNF-a was increased in the COPD 
patients of the current study and also TNF-a serum 
levels at rest correlated statistically significantly with 
serum leptin concentration. Inflammatory cytokines, 
as TNF-a or IL-1, when administrated to animals re-
sulted in an increase in circulating leptin concentra-
tion8. 
Reports concerning the effect of oral corticoste-
roids use on leptin are contradictory. Corticosteroids 
in therapeutic doses were found to have a stimulat-
ing effect on leptin concentrations via the induction of 
insulin resistance, as glucose and insulin can induce 
leptin expression27. On the other hand it was demon-
strated that the acute administration of corticosteroids 
had no effects on insulin, free fatty acids or leptin con-
centrations compared with placebo, while prolonged 
administration significantly increased the fasting 
concentration of insulin, but not that of glucose free 
fatty acids and leptin28. Also in stable COPD patients 
no effect of oral corticosteroids on serum leptin was 
found9. During an acute exacerbation of COPD the 
serum leptin concentration could be (in part) a result 
of high corticosteroid treatment, since the course of 
plasma leptin related with the scheme of prednisolone 
administration7. We consider that the low prolonged 
dose of oral methylprednisolone in the patients of the 
current study had insignificant effect on serum leptin. 
Leptin concentration in the patients of the study corre-
lated statistically significantly with metabolic indices 
as BMI and FFM, but no statistically significant rela-
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tion was demonstrated between serum leptin or TNF-a 
levels and exercise capacity.
Stepwise multiple regression analysis was per-
formed to determine the best combination of predic-
tors for V
O2max
. Only TMA and %FEV1 appeared to 
be significant determinants of V
O2max
. Total variance 
in this model for V
O2max
 was 52%. In contrast FFM, 
serum levels of leptin and TNF-a were not selected as 
significant predictors of V
O2max
.
The conclusion of the present study is that serum 
leptin and TNF-a levels, as markers of systemic in-
flammation in COPD patients, are related to metabol-
ic indices (like BMI, FM), but are very poor predic-
tors of maximal exercise capacity (Wmax or V
O2max
) 
in these patients. The best predictors of V
O2max
 are 
airflow limitation (%FEV1) and leg muscle mass as 
expressed by TMA.
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Circulating leptin and TNF-a levels correlated 
with BMI and % fat in COPD patients10. In malnour-
ished COPD patients, there was an inverse relation-
ship between changes in body weight after 8 weeks of 
nutritional therapy and leptin plasma concentrations9. 
The nutritional parameters that express muscle mass, 
as FFM, were reported to be associated with exercise 
performance in COPD patients11,12.
Extrapulmonary abnormalities, like systemic in-
flammation, weight loss and muscle dysfunction, de-
termined the exercise capacity of COPD patients and 
were related with leptin and TNF-a levels. The aim 
of the present study is to examine whether the limita-
tion of the exercise capacity of these patients can be 
related to the circulating serum leptin and TNF-alpha 
levels. 
MATeRIAl AND MeThODS
Thirty male patients with moderate to severe COPD, 
defined by a FEV1/FVC of less than 0.50, were evalu-
ated. Patients with other potential causes of weight loss 
such as diabetes, thyroid dysfunction, malabsorption 
syndromes, alcoholism and neoplastic diseases were 
excluded. Patients with edema forming states, i.e. re-
nal, liver or cardiac diseases, were also excluded in 
order to eliminate the effect of edema in the interpre-
tation of body weight. At the time of the study, all the 
patients were stable and all received optimal medical 
therapy including a low dose of methylprednisolone 
(4-8 mg every other day) for 1-2 months (mean dura-
tion 37± 12 days). Corticosteroid treatment was in-
stalled in our COPD patients during last exacerbation 
and tapered in small doses. None of our subjects were 
in long term high doses oral corticosteroid treatment. 
The study was approved by the Ethics Committee of 
the G Papanikolaou Hospital (University Hospital) of 
Thessaloniki. All patients gave written informed con-
sent before inclusion.
Spirometry was performed with a computerized 
spirometer (Jaeger) and Forced Expiratory Volume in 
one second (FEV1), Forced Vital Capacity (FVC) and 
the ratio FEV1/FVC (FEV1%) were calculated accord-
ing to the ATS recommendations13. The results were 
expressed as absolute values and as percent of the pre-
dicted values.
Body height (h) was determined to the nearest 0.5 
cm (Lameris WM 715, Breukelen) with the patients 
standing barefoot. Body weight (Bw) was measured 
with a beam scale to the nearest 0.1 kg (SELA, FR-G) 
with subjects barefoot and with only underwear cloth-
ing. Body Mass Index (BMI) was calculated from 
body weight and height (BMI = Bw/h2, kg/m2).
The measurement of skinfold thickness at four 
sites (triceps, biceps, subcapular, suprailiac) was used 
to assess fat mass. Total fat mass (FM) was estimated 
using tables and free fat mass (FFM) was obtained by 
the subtraction of FM from Bw14. Forceps skinfold 
thickness (FST) and mid-thigh circumference (MTC) 
were used to calculate the mid-thigh muscle circum-
ference (MTMC). Finally, thigh muscle area (TMA) 
was calculated (TMA = MTMC2/4π)15.
Exercise testing was done on a cycle ergometer 
(cardiopulmonary Diagnostic System Med Graph-
ics), using the standard 1-min incremental cycle ex-
ercise protocol. Patients began with a 2-min period of 
unloaded pedaling at 60 cycles/min, followed by 10 
Watt increments per minute. The patients were strong-
ly encouraged to cycle to the point of discomfort or 
exhaustion or until an abnormal electrocardiogram 
(ECG) was noted (symptom-limited exercise tests). 
Heart Rate (HR) and cardiac rhythm were monitored 
with a three-lead ECG and blood pressure was mea-
sured with auscultation.
Minute ventilation and its components were mea-
sured with a pneumotachograph. The concentrations 
of expired O2 and CO2 were analyzed breath by breath 
with a zirconium dioxide-cell O2 analyzer and an 
infrared CO2 analyzer respectively. These measure-
ments and the pneumonotachograph flow signals were 
integrated electronically by a computerized system to 
yield 10-s averages of minute ventilation (VE), tidal 
volume (VT), respiratory rate (RR), oxygen uptake 
(VO2), carbon dioxide output (VCO2) and gas exchange 
ratio (R). HR was also measured and was used to 
obtain the HR reserve (HRmax/predHRmax %) and 
O2 pulse (VO2/HR). Maximal O2 pulse (O2Pmax) was 
measured at the point at which O2 pulse reached a 
plateau or patients were exhausted. Predicted Maxi-
mal Voluntary Ventilation (MVV) was expressed as 
MVV= FEV1 x 35, in units of L/min, and predicted 
maximal HR (HRmax) was calculated as 210- (age x 
0.65)15. Arterial hemoglobin oxygen saturation (SaO2) 
was monitored non invasively with a pulse oximeter. 
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For leptin levels determination blood samples 
were drawn between 8-9 a.m. after fasting the pre-
vious night. The samples were stored at -70oC until 
analysis. Serum leptin levels were determined using a 
competitive enzyme immunoassay (Accucyte, Mery-
land USA). TNF-a levels were determined in serum 
using Pelikine Compact human TNF-a ELISA kits 
(CLB, Amsterdam). The specificity of the ELISA kit 
is 0-1000 pg/mL for TNF-a. In 10 normal subjects 
(age 63+5y) the serum leptin levels were 3.67 +0.7 
ng/mL and TNF-a levels were 3.11+ 0.45 pg/mL.
STATISTICAl ANAlySIS
Values obtained were expressed as mean + SD. Pear-
son’s correlation coefficients were calculated among 
VO2max or maximal exercise capacity (in watts) and 
different metabolic and exercise parameters. Stepwise 
multiple regression analysis was performed to deter-
mine the best predictors of VO2max. 
ReSUlTS
Anthropometric and lung function data of our 30 
COPD patients (mean age 68,7+1.06 years) presented 
in Table 1. TNF-a levels were 9.58+0.56 pg/mL (range 
5.65-16.7 pg/mL) and serum leptin concentration was 
9.37+1.7ng/mL (range 1.17-37.4 ng/mL), increased in 
relation to our normal values.
There was a significant correlation between se-
rum TNF-a and leptin levels (r = 0.521, p < 0.001). 
Also there were significant correlations between se-
rum leptin levels, BMI (r = 0.421, p < 0.02) and FM 
(r = 0.551, p < 0.01), but no correlations were found 
between serum leptin levels and other nutritional pa-
rameters such as FFM, MTMC or TMA. Also no cor-
relations were found between nutritional parameters 
like BMI, FM, FFM, MTMC, TMA and serum TNF-a 
levels.
The exercise capacity, the ventilatory and cir-
culatory parameters during maximal exercise of 
the COPD patients of the study are presented in ta-
ble 2. Patients with COPD achieved a work capac-
ity (Wmax) of 42.6+5.43 watts (30.2+3.43% of pre-
dicted normal values). VEmax was 31.3+2.05 L/min, 
MVV was 35.98+2.48 L/min and VEmax/MVV was 
95.8+3.87. VO2max was decreased (786+57mL/min). 
Maximal heart rate (HRmax) was 121.7+5 beats/min 
(85.7+2.3% of predicted). The oxygen pulse (VO2max/
HRmax) was decreased during maximal exercise 
(6.47+1.17 mL/beat).
The correlations between exercise capacity (Wmax 
or VO2max) and ventilatory, circulatory and nutritional 
parameters are presented in table 3. The exercise ca-
pacity correlated significantly with %FEV1 and oxy-
Table 1. Study population: anthropometric and spirometric data (mean + SE).
Age, years 68.7+1.06
Weight, kg 71.5+2.74
BMI, kg/m2 26.1+0.95
FM, kg 20.9+1.53
FFM, kg 50.8+1.60
MTMC, cm 44.4+1.97
TMA, cm2 121.7+8.39
FVC, L 2.18+0.10
FEV1, L/sec 1.02+0.05
% FEV1 43.1+1.84
TLC, %pred 92.1+3.96
BMI: body mass index, FM: fat mass, FFM: fat free mass, MTMC: mid-thigh muscle circumference, TMA: thigh muscle 
area, FVC: Forced Vital Capacity, FEV1: Forced Expiratory Volume in one second, TLC: Total Lung Capacity.
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gen pulse (VO2/HR) but not with VEmax/MVV or HR-
max. The exercise capacity correlated significantly 
better with BMI and TMA than with FFM. We found 
no correlations between leptin and TNF-a serum lev-
els and exercise capacity of the COPD patients of the 
study.
Stepwise multiple regression analysis was per-
formed to determine the best predictors for VO2max. It 
demonstrated that % FEV1 and TMA were significant 
determinants of VO2max. In contrast serum leptin and 
TNF-a were not selected as significant predictors of 
VO2max. According to the above VO2max was expressed 
as: 
VO2max = 0.329 % FEV1 + 0.495 TMA + 211 
(R2 = 0.520) 
DISCUSSION
COPD patients stop exercise when either dyspnea or 
leg effort reach a severe intensity. Dyspnea-limited 
exercise is more frequent in patients with severe air-
flow limitation and VO2max is a more objective index 
of work during maximal exercise than dyspnea or leg 
effort sensation. It is open to question whether maxi-
mal ventilatory and circulatory capacities are actually 
reached during exercise.
In the present study the work capacity was signifi-
cantly decreased in patients with severe airflow limi-
tation. In the COPD patients of the current study the 
work capacity (expressed as Wmax or VO2max) related 
to the flow limitation (%FEV1), but not to the dyspnoe-
ic index (VEmax/MVV) (table 3). Also the work capac-
Table 2. Exercise capacity, ventilatory and circulatory parameters (mean + SE).
Wmax, Watts 42.57+5.43
Wmax, %pred 30.20+3.43
VO2max, mL/min 786+57
VEmax, L/min 31.30+2.05
VEmax/MVV, % 95.80+3.87
HRmax , b/min 121.70+5.00
HRmax/ HRpred, % 85.7+2.30
VO2max/ HRmax, mL 6.47+1.17
MVV, L/min 35.98+2.48
Wmax: work capacity, VO2max: maximal oxygen uptake, VEmax: maximal ventilation, HRmax: maximal heart rate, VO2max/ 
HRmax: maximal oxygen pulse, MVV: Maximal Voluntary Ventilation.
Table 3. Correlation coefficients (r) between exercise capacity (Wmax, VO2max), ventilatory, circulatory, nutritional param-
eters, leptin and TNF-a levels. 
Work 
capacity
% FEV1 VEmax/MVV
(%)
HRmax/pred
(%)
VO2/HR
mL
BMI
Kg/m2
FFM
kg
TMA
cm2
Leptin
ng/mL
TNF-a
pg/mL
Wmax, 
watts
0.435
p<0.05
0.232
NS
0.093
NS
0.775
p<0.001
0.578
p<0.001
0.295
NS
0.623
p<0.001
-0.013
 NS
0.068
NS
VO2max, ,
mL/min
0.563
p<0.01
0.245
NS
0.09
NS
0.917
p<0.001
0.636
p<0.001
0.415
p<0.02
0.651
p<0.001
0.208
NS
0.250
NS
Wmax: work capacity, MVV: Maximal Voluntary Ventilation, VO2max: maximal oxygen uptake, VEmax: maximal ventilation, 
HRmax: maximal heart rate, VO2max/ HRmax: maximal oxygen pulse, BMI: body mass index, FFM: fat free mass, TMA: 
thigh muscle area.
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ity related with the oxygen pulse (VO2max/HRmax), 
but not with the maximal heart rate (HRmax/HRmax 
pred). 
The absence of statistically significant correlations 
between exercise capacity and ventilatory (VEmax/
MVV) or circulatory (HRmax/ HRmax pred) param-
eters in the present study suggested that most subjects 
stopped exercise at submaximal heart rate and venti-
lation. Possibly the symptoms rather than the physio-
logic factors limited the work capacity16. Hence it was 
reasonable to expect that the average patient would 
stop exercise when dyspnoea (mainly related to flow 
limitation) or the intensity of symptoms of leg effort 
were maximal.
Weight loss commonly occurs in patients with 
COPD and it is not only an epiphenomenon of the se-
verity of the disease but also an independent death risk 
factor. Weight loss and muscle wasting are factors ex-
erting several adverse effects on physical performance 
and respiratory muscle function, independently of the 
degree of airflow obstruction17-19. In this study patients 
with COPD and low BMI had diminished VO2max dur-
ing exercise.
FFM that represents muscles mass is associat-
ed with respiratory muscles strength20 and exercise 
performance11. The patients of the study with the 
higher FFM had an increased VO2max during exercise 
(r = 0.415, p < 0.02). Total FFM was a significant de-
terminant of VO2max in patients with COPD
21.
The distribution of muscle mass wasting is a fac-
tor that has to be elucidated, since muscle strength 
is closely related to muscle mass in patients with 
COPD21. FFM of legs is a significant predictor of 
maximal exercise performance in patients with mod-
erate airflow limitation22. TMA of the patients of this 
study reflected the muscle mass of the legs and corre-
lated better with VO2max, compared with FFM.
Body composition analysis by dual energy X-ray 
absorptiometry in COPD patients with severe airflow 
limitation demonstrated disproportional leg muscle 
wasting21. The distribution of muscle wasting found in 
COPD patients was not related to the atrophy induced 
by malnutrition. In malnutrition the loss of upper-limb 
function was equal or greater than that of the lower 
limbs23. In contrast in patients with severe COPD a 
disproportional leg muscle wasting was found. The 
leg muscle wasting could be attributed to the limita-
tion of the daily activity of COPD patients and also to 
the limited respiratory reserve22,23.
Systemic inflammation plays an important role in 
skeletal muscles dysfunction in COPD patients. The 
systemic inflammation is a characteristic feature of 
COPD and is demonstrated by the increased numbers 
of neutrophils, macrophages and T-lymphocytes, as 
well as by the elevated concentrations of pro-inflam-
matory cytokines and by the oxidative stress. In clini-
cally stable patients, but especially during the exacer-
bations of the disease, increased levels of cytokines, 
such TNF-a and its receptors (TNFR-55, TNFR-75), 
interleukin -6 and -8 (IL-6, IL-8), as well as elevated 
levels of acute phase proteins, like C-reactive protein 
(CRP) and liposaccharide-binding protein (LBP) were 
found24,25. Submaximal exercise induced an abnormal 
increase in plasma TNF-a and IL-6 in patients with 
COPD [26]. Serum TNF-a was increased in the COPD 
patients of the current study and also TNF-a serum 
levels at rest correlated statistically significantly with 
serum leptin concentration. Inflammatory cytokines, 
as TNF-a or IL-1, when administrated to animals re-
sulted in an increase in circulating leptin concentra-
tion8. 
Reports concerning the effect of oral corticoster-
oids use on leptin are contradictory. Corticosteroids 
in therapeutic doses were found to have a stimulat-
ing effect on leptin concentrations via the induction of 
insulin resistance, as glucose and insulin can induce 
leptin expression27. On the other hand it was demon-
strated that the acute administration of corticosteroids 
had no effects on insulin, free fatty acids or leptin con-
centrations compared with placebo, while prolonged 
administration significantly increased the fasting 
concentration of insulin, but not that of glucose free 
fatty acids and leptin28. Also in stable COPD patients 
no effect of oral corticosteroids on serum leptin was 
found9. During an acute exacerbation of COPD the 
serum leptin concentration could be (in part) a result 
of high corticosteroid treatment, since the course of 
plasma leptin related with the scheme of prednisolone 
administration7. We consider that the low prolonged 
dose of oral methylprednisolone in the patients of the 
current study had insignificant effect on serum leptin. 
Leptin concentration in the patients of the study corre-
lated statistically significantly with metabolic indices 
as BMI and FFM, but no statistically significant rela-
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tion was demonstrated between serum leptin or TNF-a 
levels and exercise capacity.
Stepwise multiple regression analysis was per-
formed to determine the best combination of predic-
tors for VO2max. Only TMA and %FEV1 appeared to 
be significant determinants of VO2max. Total variance 
in this model for VO2max was 52%. In contrast FFM, 
serum levels of leptin and TNF-a were not selected as 
significant predictors of VO2max.
The conclusion of the present study is that serum 
leptin and TNF-a levels, as markers of systemic in-
flammation in COPD patients, are related to metabolic 
indices (like BMI, FM), but are very poor predictors 
of maximal exercise capacity (Wmax or VO2max) in 
these patients. The best predictors of VO2max are air-
flow limitation (%FEV1) and leg muscle mass as ex-
pressed by TMA.
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